Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. - Ristic,S.; Byiers,S.; Foley,J.; Holmes,D. (Diabetes Obes Metab, 2005)